Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype

J Virol. 2013 Jul;87(13):7593-607. doi: 10.1128/JVI.02824-12. Epub 2013 May 1.

Abstract

Cell culture-produced hepatitis C virus (HCV) has been subjected to up to 100 serial passages in human hepatoma cells in the absence or presence of different doses of alpha interferon (IFN-α). Virus survival, genetic changes, fitness levels, and phenotypic traits have been examined. While high initial IFN-α doses (increasing from 1 to 4 IU/ml) did not allow HCV survival beyond passage 40, a gradual exposure (from 0.25 to 10 IU/ml) allowed the virus to survive for at least 100 passages. The virus passaged in the presence of IFN-α acquired IFN-α resistance as evidenced by enhanced progeny production and viral protein expression in an IFN-α environment. A partial IFN-α resistance was also noted in populations passaged in the absence of IFN-α. All lineages acquired adaptative mutations, and multiple, nonsynonymous mutations scattered throughout the genome were present in IFN-α-selected populations. Comparison of consensus sequences indicates a dominance of synonymous versus nonsynonymous substitutions. IFN-α-resistant populations displayed decreased sensitivity to a combination of IFN-α and ribavirin. A phenotypic trait common to all assayed viral populations is the ability to increase shutoff host cell protein synthesis, accentuated in infections with IFN-α-selected populations carried out in the presence of IFN-α. The trait was associated with enhanced phosphorylation of protein kinase R (PKR) and eIF2α, although other contributing factors are likely. The results suggest that multiple, independent mutational pathways can confer IFN-α resistance to HCV and might explain why no unified picture has been obtained regarding IFN-α resistance in vivo.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptation, Biological / genetics*
  • Base Sequence
  • Blotting, Western
  • Cell Line, Tumor
  • DNA Primers / genetics
  • Dose-Response Relationship, Drug
  • Drug Resistance / genetics
  • Hepacivirus / drug effects
  • Hepacivirus / genetics*
  • Humans
  • Interferon-alpha / pharmacology*
  • Molecular Sequence Data
  • Mutation / drug effects
  • Mutation / genetics
  • Phenotype*
  • Real-Time Polymerase Chain Reaction
  • Sequence Analysis, DNA
  • Serial Passage / methods

Substances

  • DNA Primers
  • Interferon-alpha

Associated data

  • GENBANK/KC595606
  • GENBANK/KC595607
  • GENBANK/KC595608
  • GENBANK/KC595609
  • GENBANK/KC595610
  • GENBANK/KC595611
  • GENBANK/KC595612
  • GENBANK/KC595613
  • GENBANK/KC595614
  • GENBANK/KC595615
  • GENBANK/KC595616
  • GENBANK/KC595617
  • GENBANK/KC595618
  • GENBANK/KC595619
  • GENBANK/KC595620
  • GENBANK/KC595621
  • GENBANK/KC595622
  • GENBANK/KC595623
  • GENBANK/KC595624